Home » , , , , , » Healthcare Sector - Valuations running high‏

Healthcare Sector - Valuations running high‏

Shared By Stock Fanatic on Monday, June 22, 2015 | 22.6.15


■ FSTHC outperformed STI

■ But sector looking less attractive

■ Growth stories may be priced in

Rewarding sector but valuations seem stretched
While our local bourse has been rather lacklustre, the healthcare sector paints a starkly different picture as the FTSE ST Health Care Index (FSTHC) has delivered a 36% gain YTD compared to -2.1% by the STI benchmark. The often-quoted supportive long-term outlook for healthcare plays amid uncertain times has made them a comparably rewarding haven for investors. However, we note that broad-based valuations currently seem stretched as the index is trading above 1 s.d. of its two-year historical forward P/E average with a sixyear historical high forward P/E of 26.5x. We keep our NEUTRAL stance on the sector as we think such premium valuations are warranted only to a certain extent, while a deeper look into specific companies suggest growth stories may already be priced in and a potential correction could be due.

Clear growth story for hospital players but margin pressure in near-term
We had previously covered several healthcare companies’ plans to expand in China given the attractive growth prospects, but also highlighted operational risks and early stage of plans as caveats for a more optimistic stance. Under our coverage, share price for Raffles Medical Group [HOLD, $4.17] has had a largely sustained run-up since its confirmation on a Shanghai Hospital, which is slated for completion by mid-18. 

While this is a positive development, in the meantime, its 1Q15 results showed that higher expenses such as staff costs would likely be incurred due to other upcoming projects (Holland Village project to be ready by 1Q16 and Raffles Hospital extension by 1Q17). 

Peers such as IHH Healthcare Berhad [non-rated] could also face similar near-term pressures on operating margins due to on-going expansion plans in Malaysia and Turkey. With both stocks trading at more than 1 s.d. above their two-year historical forward P/E average, current valuations are becoming less attractive.

Are expectations running too fast?
We reiterate that a fundamental growth story would take time to materialise for Biosensors International Group [SELL, $0.60]. In addition, Boston Scientific’s Synergy stent may also take the lead, as it could be the first resorbable stent to receive FDA approval by end-15. The recent MERS outbreak in South Korea and depreciation of MYR against the USD have also led attention to healthcare suppliers, as Riverstone, UG Healthcare (UGHC) and Medtecs International [nonrated] have seen their share price rise to new levels, gaining 65%, 31%, 23% YTD respectively. We think the above factors are temporary while the companies’ own growth story may be priced in. As such, there could be some potential selloff ahead as peers like Hartalega have showed a hint of price correction. (Read Report)

Source : OCBC Investment Research


Posted on Monday, June 22, 2015 | 22.6.15
With No comments


Join Me On: Facebook | Twitter | Google Plus ::: Thank you for visiting ! :::
DISCLAIMER:
Some of the photos shown in this blog are randomly sourced from the Public Domain. If there is an infringement in the copyright of the photos; kindly inform us and it will be removed immediately. Thank you for your kind understanding.
Share this article :

Post a Comment

 
Modified by : Stockfanatic
Copyright © 2008 - 2018. Singapore Stock Market News - All Rights Reserved
Template Created by Creating Website Published by Mas Template
Proudly powered by Blogger
Related Posts with Thumbnails